Noninvasive diagnosis of secondary infections in COVID-19 by sequencing of plasma microbial cell-free DNA.

Background: Secondary infection (SI) diagnosis in COVID-19 is challenging, due to overlapping clinical presentations, practical limitations in obtaining samples from the lower respiratory tract (LRT), and low sensitivity of microbiologic cultures. Research Question: Can metagenomic sequencing of plasma microbial cell-free DNA (mcfDNA-Seq) help diagnose SIs complicating COVID-19? Study Design and Methods: We enrolled 42 inpatients with COVID-19 classified as microbiologically-confirmed SI (Micro-SI, n=8), clinically-diagnosed SI (Clinical-SI, n=13, i.e. empiric antimicrobials), or no clinical suspicion for SI (No-Suspected-SI, n=21) at time of enrollment. From baseline and follow-up plasma samples (days 5 and 10 post-enrollment), we quantified mcfDNA for all detected microbes by mcfDNA sequencing and measured nine host-response biomarkers. From LRT samples among intubated subjects, we quantified bacterial burden with 16S rRNA gene quantitative PCR. Results: We performed mcfDNA-Seq in 82 plasma samples. Sequencing was successful in 60/82 (73.2%) samples, which had significantly lower levels of human cfDNA than failed samples (p<0.0001). McfDNA detection was significantly higher in Micro-SI (15/16 [94%]) compared to Clinical-SI samples (8/14 [57%], p=0.03), and unexpectedly common in No-Suspected-SI samples (25/30 [83%]), similar to detection rate in Micro-SI. We detected culture-concordant mcfDNA species in 13/16 Micro-SI samples (81%) and mcfDNA levels tracked with SI outcome (resolution or persistence) under antibiotic therapy. McfDNA levels correlated significantly with LRT bacterial burden (r=0.74, p=0.02) as well as plasma biomarkers of host response (white blood cell count, IL-6, IL-8, and SPD, all p<0.05). Baseline mcfDNA levels were predictive of worse 90-day survival (hazard ratio 1.30 [1.02-1.64] for each log10 mcfDNA, p=0.03). Interpretation: High circulating levels of mcfDNA in a substantial proportion of patients with COVID-19 without clinical suspicion for SI suggest that SIs may often remain undiagnosed. McfDNA-Seq, when clinically available, can offer a non-invasive diagnostic tool for pathogen identification, with prognostic value on host inflammatory response and clinical outcomes.

[1]  B. Methé,et al.  Radiographic Lung Edema in Hospitalized Patients with COVID-19 Is Associated with Disease Severity and Clinical Outcomes , 2022, B104. COVID ACROSS THE CARE CONTINUUM.

[2]  J. Wiemer,et al.  Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study , 2022, PloS one.

[3]  Janet S. Lee,et al.  Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract SARS-CoV-2 infection in critically ill patients with COVID-19. , 2022, medRxiv.

[4]  J. Timsit,et al.  HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients , 2021, Critical Care.

[5]  Yingze Zhang,et al.  Biomarker-Based Classification of Patients With Acute Respiratory Failure Into Inflammatory Subphenotypes: A Single-Center Exploratory Study , 2021, Critical care explorations.

[6]  Jordan J. Clark,et al.  Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study , 2021, The Lancet. Microbe.

[7]  C. Missouris,et al.  Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection , 2021, Annals of clinical biochemistry.

[8]  G. Kitsios,et al.  Circulating microbial cell-free DNA is associated with inflammatory host-responses in severe pneumonia , 2021, Thorax.

[9]  G. Kitsios,et al.  Seek and Ye Shall Find: COVID-19 and Bacterial Superinfection , 2021, American journal of respiratory and critical care medicine.

[10]  R. Wunderink,et al.  Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia , 2021, American journal of respiratory and critical care medicine.

[11]  Janet S. Lee,et al.  COVID-19 versus Non–COVID-19 Acute Respiratory Distress Syndrome: Comparison of Demographics, Physiologic Parameters, Inflammatory Biomarkers, and Clinical Outcomes , 2021, Annals of the American Thoracic Society.

[12]  R. Duttagupta,et al.  Plasma microbial cell-free DNA load is associated with mortality in patients with COVID-19 , 2021, Respiratory Research.

[13]  R. Wunderink,et al.  Bronchoscopy on Intubated Patients with COVID-19 Is Associated with Low Infectious Risk to Operators , 2021, Annals of the American Thoracic Society.

[14]  D. MacFadden,et al.  Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis , 2021, Clinical Microbiology and Infection.

[15]  P. Póvoa,et al.  Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study , 2021, Intensive Care Medicine.

[16]  H. Donaldson,et al.  Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting , 2020, Clinical Microbiology and Infection.

[17]  P. Benos,et al.  The evolution of radiographic edema in ARDS and its association with clinical outcomes: A prospective cohort study in adult patients. , 2019, Journal of critical care.

[18]  Martin S. Lindner,et al.  Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease , 2019, Nature Microbiology.